

3. Provision of sufficient clinical information to ensure that the proper choice of growth medium, probe sets, and analytic techniques are made

REFERENCES

- 1) Clinical and Laboratory Standards Institute (CLSI). *Developing and Using Quality Indicators for Laboratory Improvement*. 2nd ed. CLSI guideline QMS12. Clinical and Laboratory Standards Institute, Wayne, PA; 2019.

CYG.20800 Procedure Failures

Phase II



The number or frequency of culture failures, hybridization failures, and/or suboptimal analyses is recorded, and there are records of corrective action when adverse trends occur.

QUALITY CONTROL (QC)

SUPERVISION OF QUALITY CONTROL

Inspector Instructions:

READ 	<ul style="list-style-type: none"> • Sampling of QC policies and procedures • Sampling of QC records • Records of final report error investigation
ASK 	<ul style="list-style-type: none"> • How do you determine when QC is unacceptable and when corrective actions are needed?
DISCOVER 	<ul style="list-style-type: none"> • Select several occurrences in which QC is out of range and determine whether the steps taken follow the laboratory procedure for corrective action.

CYG.30066 Monthly QC Review

Phase II

The laboratory director or designee reviews and assesses quality control data at least monthly.

NOTE: QC data may include specimen handling, culture failures, new media QC, new reagent lot verification, etc. The reviewer must record follow-up for outliers, trends, or omissions that were not previously addressed.

The QC data for tests performed less frequently than once per month may be reviewed when the tests are performed.

Evidence of Compliance:

- ✓ Records of QC review **AND**
- ✓ Records of corrective action taken when acceptability criteria are not met

CYG.30325 Reporting Error Investigation

Phase II